58 documents on Sun Pharmaceutical Industries Ltd.: 12 annual reports, 5 investor presentations, 22 analyst and investor calls: notices, recordings, transcripts, 16 press releases, 3 credit rating letters. Annual reports from the exchange's archive; the rest from twelve months of Regulation 30 announcements, in the exchange's own categories, each linked to the PDF the company filed.
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated September 01, 2026, titled "Sun Pharma Participates in White House Signing Ceremony Highlighting U.S. Medicines Pricing and Access Commitments".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 29, 2026, titled "Sun Pharma receives approval to manufacture and market semaglutide in Brazil".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 24, 2026, titled "Sun Pharma Notes Organon Shareholder Approval for Proposed Acquisition".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 15, 2026, titled "Sun Pharma receives approval to manufacture and market generic semaglutide in South Africa".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated May 26, 2026, titled "At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT (cosibelimab-ipdl)".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated April 27, 2026, titled "Investor call to discuss the acquisition of Organon & Co.".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 27, 2026, titled "Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated January 23, 2026, titled Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management, .
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated December 01, 2025, titled "Sun Pharma introduces its global innovative drug, Ilumya® inIndia for treatment of moderate-to-severe Plaque Psoriasis".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated November 17, 2025, titled "AstraZeneca Pharma India Limited and Sun Pharma partner to help patients living with Hyperkalaemia in India".
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated November 12, 2025, titled "Philogen provides update on Fibromun clinical study developments".
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.